Eperisone/pelubiprofen - Daewon Pharmaceutical
Alternative Names: DW 340; Pelubiprofen/eperisone - Daewon PharmaceuticalLatest Information Update: 05 Oct 2021
Price :
$50 *
At a glance
- Originator Daewon Pharmaceutical
- Class Analgesics; Antiepileptic drugs; Antipyretics; Antirheumatics; Cyclohexanes; Muscle relaxants; Neuroprotectants; Non-opioid analgesics; Nonsteroidal anti-inflammatories; Piperidines; Propiophenones; Small molecules; Vasodilators
- Mechanism of Action Calcium channel antagonists; Cyclooxygenase inhibitors; Immunosuppressants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Back pain
Most Recent Events
- 05 Oct 2021 No development reported - Phase-II for Back pain (PO) (Daewon Pharmaceutical website, October 2021)
- 28 Nov 2018 No recent reports of development identified for phase-I development in Back-pain(In volunteers) in South Korea (PO)